查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088180

骨關節炎鎮痛藥市場：2026-2032年全球市場預測（按產品類型、給藥途徑、疾病嚴重程度、最終用戶、應用和分銷管道分類）

Osteoarthritis Pain Drug Market by Product Type, Route Of Administration, Disease Severity, End User, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，骨關節炎止痛藥市場規模將成長至 179.9 億美元，複合年成長率為 9.62%。

主要市場統計數據
基準年 2025 94.5億美元
預計年份：2026年 103.1億美元
預測年份 2032 179.9億美元
複合年成長率 (%) 9.62%

骨關節炎止痛藥的需求主要源自於疾病帶來的沉重且持續的負擔。根據世界衛生組織（世衛組織）估計，2019年全球有5.28億人患有骨關節炎，是1990年的兩倍多。許多患者年齡超過55歲，女性盛行率顯著高於男性。在美國，疾病管制與預防中心（CDC）報告稱，超過3,250萬成年人患有骨關節炎，凸顯了可治療疼痛患者的數量之多。

該市場受對安全有效的長期疼痛管理方案的需求所驅動，這些方案涵蓋外用非類固醇消炎劑(NSAIDs)、口服 NSAIDs、乙醯胺酚、Duloxetine、關節內注射皮質類固醇以及某些輔助性治療。目前的臨床指引優先考慮個人化治療、降低風險和改善功能，這為開發差異化的骨關節炎鎮痛藥創造了新的機遇，這些藥物能夠提高耐受性、依從性和可衡量的患者療效。

骨關節炎疼痛管理的變革性變化

骨關節炎疼痛管理的策略正從單純抑制症狀轉向以患者整體為考量的風險調整型疼痛管理。在選擇鎮痛療法時，臨床醫生越來越重視消化器官系統、心血管、腎臟、代謝以及與老齡化相關的安全性因素，尤其是在患有多種慢性疾病的老年患者中。

人工智慧（AI）對骨關節炎疼痛藥物治療的累積影響

人工智慧（AI）正成為骨關節炎疼痛藥物整個價值鏈中一股實質的驅動力。 AI驅動的影像分析、電子健康記錄挖掘、臨床記錄的自然語言處理以及生物標記發現，正幫助識別疼痛表現型、預測疾病進展並改善臨床試驗中的患者選擇。

針對全球骨關節炎鎮痛藥需求的關鍵區域洞察。

由於日本、中國、韓國、澳洲以及部分東協國家人口老化，導致膝關節、髖關節和手部骨關節炎患者數量增加，亞太地區成為重點關注區域。印度和中國人口眾多，診斷率不斷提高，品牌學名藥廣泛普及，醫院網路完善，門診疼痛管理服務日益增多，這些因素進一步擴大了市場規模。日本人口老化和澳洲以指引為基礎的醫療保健體係也進一步推動了對更安全、更持久的骨關節炎疼痛管理方案的需求。

小組對骨關節炎鎮痛策略的關鍵見解

東南亞國協的需求主要受人口老化、城市生活方式、非傳染性疾病負擔加重以及藥房覆蓋範圍擴大等因素驅動，儘管各國的保險報銷範圍和監管時間表有所不同。海灣合作理事會（GCC）市場則受到肥胖和代謝性疾病高發生率的影響，這些疾病被認為是骨關節炎的風險因子。此外，海灣合作理事會對醫院、專業醫療基礎設施和數位醫療系統的大力投資也推動了市場需求。

各國對骨關節炎疼痛管理的見解

美國是最大的單一商業參考點，這得益於美國疾病管制與預防中心（CDC）記錄的骨關節炎盛行率、先進的疼痛照護網路、臨床指南的廣泛應用以及商業性嚴格的審核。在加拿大，基於實證醫學的報銷機制和省級准入管道已經建立。同時，墨西哥和巴西的需求正在成長，這得益於公共和私人醫療保健管道的擴展以及慢性病管理的完善。在英國、德國、法國、義大利和西班牙，國家醫療體系、醫療技術評估、醫生對指南的採納以及對成本效益處方的重視正在塑造市場。然而，在俄羅斯，當地的註冊要求、採購趨勢和國內准入條件仍然產生影響。

為骨關節炎疼痛緩解領域的領導企業提供實用建議

產業領導企業應優先考慮差異化的安全性特徵，尤其要關注因胃腸道、心血管、腎臟、代謝或多重用藥等問題而處於高風險的患者。研發項目應納入老年患者、合併其他疾病的患者以及真實世界的疼痛模式，以增強臨床相關性，並反映骨關節炎疼痛管理在日常實踐中的實際情況。

基於證據的市場分析調查方法

本執行摘要基於權威公共衛生機構的二手研究、臨床指南、法律規範、同行評審文獻和醫療政策資訊來源。主要疾病負擔參考數據包括世界衛生組織全球骨關節炎估計數據和美國疾病控制與預防中心骨關節炎數據。

關於骨關節炎止痛藥市場的結論

骨關節炎止痛藥市場需求旺盛，主要受全球龐大患者群體、人口老化以及對有效、安全、長期疼痛管理方案持續存在的未滿足需求所驅動。儘管現有療法仍然至關重要，但隨著臨床醫生在緩解疼痛的同時權衡合併症風險和耐受性，治療方案的選擇正變得更加個人化、循證和注重安全性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：骨關節炎鎮痛藥市場：依產品類型分類

  • 皮質類固醇
  • Cyclooxygenase2抑制劑
  • 非類固醇類抗發炎藥
  • 症狀治療的緩釋藥物
  • 黏彈性補充劑

第8章：骨關節炎鎮痛藥市場：依給藥途徑分類

  • 注射藥物
    • 關節內給藥
    • 肌肉內部
  • 口服
    • 膠囊
    • 液體
    • 藥片
  • 外用
    • 奶油
    • 凝膠
    • 修補

第9章：骨關節炎鎮痛藥市場：依疾病嚴重程度分類

  • 溫和的
  • 緩和
  • 嚴重

第10章：骨關節炎鎮痛藥市場：依最終用戶分類

  • 診所
  • 家庭醫療保健
  • 醫院

第11章 骨關節炎鎮痛藥市場：依應用領域分類

  • 膝關節骨關節炎
  • 髖關節骨關節炎
  • 手部骨關節炎
  • 脊椎骨關節炎

第12章：骨關節炎鎮痛藥市場：依通路分類

  • 離線
  • 線上

第13章：骨關節炎止痛藥市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 骨關節炎鎮痛藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：骨關節炎止痛藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc
  • Alkem Laboratories Ltd
  • Amgen Inc
  • Astellas Pharma Inc
  • Aurobindo Pharma Ltd
  • Bayer AG
  • Biocon Ltd
  • Bristol Myers Squibb Company
  • Cipla Ltd
  • Dr Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd
  • Ipca Laboratories Ltd
  • Johnson & Johnson
  • Lupin Ltd
  • Mankind Pharma Ltd
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Roche Holding AG
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd
  • UCB SA
  • Viatris Inc
  • Zydus Lifesciences Ltd
Product Code: MRR-0376B2CAAFEB

The Osteoarthritis Pain Drug Market is projected to grow by USD 17.99 billion at a CAGR of 9.62% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.45 billion
Estimated Year [2026] USD 10.31 billion
Forecast Year [2032] USD 17.99 billion
CAGR (%) 9.62%

Osteoarthritis pain drug demand is anchored in a large, persistent disease burden. The World Health Organization estimated that 528 million people were living with osteoarthritis in 2019, more than double the 1990 level, with most patients older than 55 and women disproportionately affected. In the United States, the CDC reports that more than 32.5 million adults have osteoarthritis, reinforcing the scale of the treatable pain population.

The market is shaped by the need for safe, long-term pain control across topical nonsteroidal anti-inflammatory drugs (NSAIDs), oral NSAIDs, acetaminophen, duloxetine, intra-articular corticosteroids, and selected adjunctive therapies. Current clinical guidelines prioritize individualized care, risk reduction, and functional improvement, creating opportunities for differentiated osteoarthritis pain drugs that improve tolerability, adherence, and measurable patient outcomes.

Transformative Shifts in the Osteoarthritis Pain Landscape

The osteoarthritis pain treatment landscape is shifting from symptom suppression toward whole-person, risk-adjusted pain management. Clinicians increasingly weigh gastrointestinal, cardiovascular, renal, metabolic, and age-related safety considerations when selecting analgesic therapy, especially for older adults with multiple chronic conditions.

Regulatory and payer scrutiny is also reshaping the competitive environment. Stronger caution around chronic opioid use, expanding use of topical NSAIDs for localized knee and hand pain, and greater attention to real-world evidence are pushing manufacturers to prove durable benefit, safety, and value beyond traditional pain-score endpoints.

Cumulative Impact of Artificial Intelligence on Osteoarthritis Pain Drugs

Artificial intelligence is becoming a practical accelerator across the osteoarthritis pain drug value chain. AI-enabled image analysis, electronic health record mining, natural language processing of clinical notes, and biomarker discovery can help identify pain phenotypes, predict progression, and improve patient selection for clinical trials.

The cumulative impact is especially relevant because osteoarthritis pain is heterogeneous and not always proportional to structural joint damage. Machine learning can support trial enrichment, digital pain monitoring, adherence analysis, pharmacovigilance signal detection, and payer-facing evidence generation, helping companies reduce late-stage uncertainty while improving treatment personalization.

Key Regional Insights Across Global Osteoarthritis Pain Drug Demand

Asia-Pacific is a high-priority region because aging populations in Japan, China, South Korea, Australia, and parts of ASEAN are expanding the pool of patients with knee, hip, and hand osteoarthritis. India and China add scale through large populations, rising diagnosis rates, broader use of branded generics, improving hospital networks, and expanding outpatient pain management access. Japan's older demographic profile and Australia's guideline-driven care environment further reinforce demand for safer long-term osteoarthritis pain treatment options.

North America remains a value-defining region due to strong clinical infrastructure, high awareness, and active payer evaluation in the United States and Canada. Europe benefits from mature regulatory systems, national health technology assessment pathways, and guideline-led prescribing, while Latin America is shaped by public-private access expansion in countries such as Brazil and Mexico. The Middle East is influenced by obesity, diabetes, and investment in specialty healthcare infrastructure, and Africa presents access-led opportunities where affordability, primary care capacity, and uneven specialist availability strongly affect osteoarthritis pain drug utilization.

Key Group Insights for Osteoarthritis Pain Drug Strategy

ASEAN demand is supported by population aging, urban lifestyles, rising noncommunicable disease burden, and expanding pharmacy access, although reimbursement depth and regulatory timelines differ by country. The GCC market is influenced by high rates of obesity and metabolic disease, both recognized risk factors for osteoarthritis, alongside strong investment in hospitals, specialty care infrastructure, and digital health systems.

The European Union emphasizes evidence quality, cost-effectiveness, pharmacovigilance, and post-market safety, making it central to value demonstration for osteoarthritis pain drugs. BRICS countries combine large patient pools with pricing pressure, generic competition, public procurement priorities, and local manufacturing objectives. G7 markets lead in guideline adoption, clinical research participation, patient-reported outcome use, and premium access pathways, while NATO-aligned countries increasingly prioritize medicine supply resilience, procurement continuity, and secure pharmaceutical logistics.

Key Country Insights in Osteoarthritis Pain Treatment

The United States is the largest single commercial reference point, supported by CDC-documented osteoarthritis prevalence, advanced pain care networks, broad use of clinical guidelines, and payer scrutiny. Canada follows evidence-based reimbursement and provincial access pathways, while Mexico and Brazil offer growing demand through public-private healthcare channels and expanding chronic disease management. The United Kingdom, Germany, France, Italy, and Spain are shaped by national health systems, health technology assessment, physician guideline adoption, and emphasis on cost-effective prescribing, while Russia remains influenced by local registration requirements, procurement dynamics, and domestic access conditions.

China and India are scale markets with rising diagnosis, large aging populations, high generic competition, and expanding hospital-based pain management. Japan, South Korea, and Australia emphasize aging-related need, quality standards, physician-guided therapy, and careful long-term safety evaluation. Germany and France remain important European evidence markets because of structured reimbursement and clinical assessment expectations, and the United Kingdom continues to influence osteoarthritis pain treatment practice through value-based assessment and national guideline frameworks.

Actionable Recommendations for Osteoarthritis Pain Drug Leaders

Industry leaders should prioritize differentiated safety profiles, especially for patients at elevated gastrointestinal, cardiovascular, renal, metabolic, or polypharmacy risk. Development programs should include older adults, patients with comorbidities, and real-world pain patterns to strengthen clinical relevance and align with how osteoarthritis pain is managed in routine care.

Commercial teams should pair physician education with payer-grade outcomes evidence, including function, rescue medication use, adherence, patient-reported outcomes, and healthcare utilization. Companies should also invest in digital pain tracking, decentralized trial tools, real-world evidence generation, and pharmacovigilance analytics to build credibility across regulators, clinicians, patients, and reimbursement bodies.

Research Methodology for Evidence-Based Market Analysis

This executive summary is based on secondary research from recognized public health agencies, clinical guidelines, regulatory frameworks, peer-reviewed literature, and healthcare policy sources. Key disease-burden references include WHO global osteoarthritis estimates and CDC osteoarthritis data for the United States.

The analysis applies triangulation across epidemiology, treatment guidelines, regulatory signals, access dynamics, regional healthcare infrastructure, aging demographics, and risk-factor evidence. No unsupported market-size, market-share, or growth-rate claims are used; insights are limited to verifiable disease, treatment, policy, access, and adoption indicators relevant to osteoarthritis pain drug strategy.

Conclusion on the Osteoarthritis Pain Drug Opportunity

The osteoarthritis pain drug market is sustained by a large global patient population, aging demographics, and ongoing unmet need for effective, safer long-term pain control. Established therapies remain essential, but treatment selection is becoming more personalized, evidence-driven, and safety-focused as clinicians balance pain relief with comorbidity and tolerability risks.

Future advantage will depend on demonstrating clinically meaningful pain relief, functional improvement, tolerability, adherence, and value in real-world settings. Organizations that combine strong evidence, AI-enabled development, regional access strategy, resilient supply planning, and patient-centered outcomes will be best positioned in the evolving osteoarthritis pain treatment landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Osteoarthritis Pain Drug Market, by Product Type

  • 7.1. Corticosteroids
  • 7.2. Cyclooxygenase 2 Inhibitors
  • 7.3. Nonsteroidal Anti-Inflammatory Drugs
  • 7.4. Symptomatic Slow Acting Drugs
  • 7.5. Viscosupplements

8. Osteoarthritis Pain Drug Market, by Route Of Administration

  • 8.1. Injectable
    • 8.1.1. Intra Articular
    • 8.1.2. Intramuscular
  • 8.2. Oral
    • 8.2.1. Capsules
    • 8.2.2. Liquid
    • 8.2.3. Tablets
  • 8.3. Topical
    • 8.3.1. Cream
    • 8.3.2. Gel
    • 8.3.3. Patch

9. Osteoarthritis Pain Drug Market, by Disease Severity

  • 9.1. Mild
  • 9.2. Moderate
  • 9.3. Severe

10. Osteoarthritis Pain Drug Market, by End User

  • 10.1. Clinics
  • 10.2. Home Healthcare
  • 10.3. Hospitals

11. Osteoarthritis Pain Drug Market, by Application

  • 11.1. Knee Osteoarthritis
  • 11.2. Hip Osteoarthritis
  • 11.3. Hand Osteoarthritis
  • 11.4. Spine Osteoarthritis

12. Osteoarthritis Pain Drug Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Osteoarthritis Pain Drug Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Osteoarthritis Pain Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Osteoarthritis Pain Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc
  • 17.2. Alkem Laboratories Ltd
  • 17.3. Amgen Inc
  • 17.4. Astellas Pharma Inc
  • 17.5. Aurobindo Pharma Ltd
  • 17.6. Bayer AG
  • 17.7. Biocon Ltd
  • 17.8. Bristol Myers Squibb Company
  • 17.9. Cipla Ltd
  • 17.10. Dr Reddy's Laboratories Ltd
  • 17.11. Eli Lilly and Company
  • 17.12. GlaxoSmithKline plc
  • 17.13. Glenmark Pharmaceuticals Ltd
  • 17.14. Ipca Laboratories Ltd
  • 17.15. Johnson & Johnson
  • 17.16. Lupin Ltd
  • 17.17. Mankind Pharma Ltd
  • 17.18. Merck & Co Inc
  • 17.19. Novartis AG
  • 17.20. Pfizer Inc
  • 17.21. Regeneron Pharmaceuticals Inc
  • 17.22. Roche Holding AG
  • 17.23. Sun Pharmaceutical Industries Ltd
  • 17.24. Takeda Pharmaceutical Company Limited
  • 17.25. Teva Pharmaceutical Industries Ltd
  • 17.26. Torrent Pharmaceuticals Ltd
  • 17.27. UCB SA
  • 17.28. Viatris Inc
  • 17.29. Zydus Lifesciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CYCLOOXYGENASE 2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CYCLOOXYGENASE 2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CYCLOOXYGENASE 2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NONSTEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SYMPTOMATIC SLOW ACTING DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SYMPTOMATIC SLOW ACTING DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SYMPTOMATIC SLOW ACTING DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VISCOSUPPLEMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VISCOSUPPLEMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VISCOSUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INTRA ARTICULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INTRA ARTICULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INTRA ARTICULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CREAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CREAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CREAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MILD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MILD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MILD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MODERATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MODERATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MODERATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SEVERE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SEVERE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SEVERE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL KNEE OSTEOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL KNEE OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL KNEE OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HIP OSTEOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HIP OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HIP OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HAND OSTEOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HAND OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HAND OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SPINE OSTEOARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SPINE OSTEOARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SPINE OSTEOARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 169. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 170. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 171. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 199. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 200. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 201. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 210. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 231. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. BRAZIL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED KINGDOM OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 280. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 281. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 282. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. FRANCE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 291. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 292. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. RUSSIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 299. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 300. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 301. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 302. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 304. ITALY OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 308. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 309. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 310. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 311. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 312. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. SPAIN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 329. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 330. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 331. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 332. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 333. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 334. INDIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 335. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 338. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 339. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 340. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 341. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 342. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 344. JAPAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 345. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 346. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 348. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 349. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 350. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 351. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 352. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 354. AUSTRALIA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 355. SOUTH KOREA OSTEOARTHRITIS PAIN D